Sequent Scientific Limited has informed the Exchange regarding a press release dated May 20, 2025, titled "Press Release".
VIYASH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sequent Scientific announced its Q4 FY25 and full-year FY25 results, reporting strong revenue and profit growth. Q4 FY25 revenue rose 11.2% year-on-year to ₹4,017 million, while adjusted EBITDA jumped 38.7% to ₹569 million with margins expanding 280 basis points to 14.2%. For the full year FY25, revenue grew 13.3% to ₹15,514 million and adjusted EBITDA nearly doubled, up 86.6% to ₹1,993 million, with margins improving 500 basis points to 12.8%. The company swung to a profit after tax of ₹322 million in FY25 from a loss of ₹296 million in FY24, and net debt-to-EBITDA ratio improved sharply from 3.5x to 1.9x. The proposed merger with Viyash Life Sciences is progressing on schedule, with CCI approval received and stock exchange NOC awaited before NCLT filing. On a combined basis, the merged entity would have posted FY25 revenue of ₹30,094 million (up 12.3%) and EBITDA of ₹4,539 million (up 65.7%) with 15.1% margins.
Strong double-digit revenue growth, sharp margin expansion, return to profitability, and deleveraging are positive signals for shareholders. Merger progress with Viyash and improving combined entity metrics could support positive sentiment in the stock.